BUY 2′-OXO-PCE ONLINE
BUY 2′-OXO-PCE online (also known as eticyclidone, and O-PCE) is a lesser-known novel dissociative substance of the arylcyclohexylamine class that produces dissociative, anesthetic,
2-Oxo-PCE (Deschloro-N-Ethyl-Ketamine / O-PCE) – Dissociative Research Chemical
buy-2′-oxo-pce is a closely related to Deschloroketamin, in Germany so far not subject to the BtMG, dissociative substance, which is mainly regarded as MXE replacement (similar to methoxphenidine, MXP or diphenidine) and sold in Research Chemicals shops.
It is one of the arylcyclohexylamines!
EFFECT OF 2-OXO-PCE
The effects and side effects listed here are all very subjective.
They do not always have to occur and there may be other, unmentioned effects. BUY 2′-OXO-PCE ONLINE (Then we would be pleased to comment on this!)
These lists should not serve as a guarantee, but as a guide. The effect of Dissoziativa is individually very different and also varies greatly with the dose taken.
While lower to normal dosages are still almost suitable for everyday use, high dosages trigger a very psychedelic, dissociative trip.
Motor difficulties / dissociation from the body – The body is more difficult to control. Dissociation from the body can lead to out-of-body experiences in high dosages.
Intensifying / changing the sense of touch – touch can be stimulating and vibrating.
It is described as being generally rounder and closer to MXE than those also sold as legal MXE alternatives (or ketamine alternatives), deschloroketamine, methoxphenidine, and diphenidine.
drugs Originally synthesized by chemist Wayne E. Kenney, BAY is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotectiveeffects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.
drugs has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has been licensed to KeyNeurotek Pharmaceuticals for clinical development, and is currently in Phase II trials.But its development appears has stopped.
Originally synthesized by chemist Wayne E. Kenney, is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.
Traumatic brain injury (TBI) is the most common cause of mortality and morbidity in adults under 40 years of age in industrialized countries. Worldwide the incidence is increasing, about 9.5 million people are hospitalized per year due to TBI, and the death rate is estimated to be more than one million people per year. Recently has been characterized as a structurally novel, selective and highly potent cannabinoid CB1/CB2 receptor agonist in vitro and in vivo with pronounced neuroprotective efficacy in a rat traumatic brain injury model, showing a therapeutic window of at least 5 h.